Scientists find Ozempic may slow aging itself — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Semaglutide extended median lifespan in older healthy female mice by nearly 100 days versus untreated animals, according to the NIH-funded study published in Nature.
- Danica Chen's UC Berkeley team gave 20-month-old female mice semaglutide for three months and recorded gains in muscle and cognitive function, reduced inflammation, and stronger tissue-repair gene activity.
- In a five-month head-to-head, semaglutide outperformed a 24% calorie-restricted diet: treated mice improved beyond their baseline on spatial memory and blood-sugar control while keeping metabolic rate steady, whereas the dieting group's metabolism slowed.
- NIH's Rafael de Cabo said if GLP-1 drugs do slow the underlying aging process, the wide range of clinical benefits already observed across chronic diseases would be 'exactly what you'd expect' — not isolated disease effects.
- Chen flagged future trials testing GLP-1 drugs in healthy older adults without obesity or diabetes, while noting the current study used only female mice and does not establish that Ozempic or Wegovy extend human lifespan.
Why it matters: Nearly 100 extra median days of life in already-aging, otherwise-healthy mice is a striking result — but it comes from a female-only cohort, and the source explicitly says human lifespan effects remain unproven. The most concrete next step Chen named: clinical trials in healthy older adults without obesity or diabetes, a population currently excluded from most GLP-1 prescribing.
Ask SkimNews
